The landscape of metabolic peptide research has shifted dramatically over the past decade. From the early days of single-target GLP-1 receptor agonists to the more recent emergence of dual-agonist compounds like tirzepatide, each generation of incretin-based peptides has expanded what researchers thought possible in the study of metabolic regulation. Now, a new compound is pushing the boundary further still. Retatrutide (LY3437943), developed by Eli Lilly, is a triple-agonist peptide that simultaneously engages three distinct receptor systems: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This unprecedented triple mechanism has generated significant interest across the metabolic research community — and for good reason.
In this article, we explore what makes retatrutide unique at a molecular level, review the key clinical research findings published to date, and examine why this compound represents a meaningful step forward for researchers investigating metabolic pathways, energy homeostasis, and lipid metabolism.
What Is Retatrutide?
Retatrutide is a synthetic peptide that functions as an agonist at three G protein-coupled receptors central to metabolic regulation. Structurally, it is a single molecule engineered to bind and activate:
GLP-1 receptors — involved in glucose-dependent insulin secretion, appetite regulation, and gastric motility
GIP receptors — implicated in insulin secretion, fat metabolism, and nutrient-driven metabolic signalling
Glucagon receptors — key regulators of hepatic glucose output, lipid oxidation, and energy expenditure
This makes retatrutide what is commonly referred to as a “triagonist” or “triple-agonist” — a single peptide capable of engaging all three receptor pathways simultaneously. The compound is based on a modified GIP peptide backbone, with amino acid substitutions and a fatty acid side chain that extends its half-life and enables once-weekly dosing in research protocols.
It is worth emphasising that retatrutide is classified as a research compound. All references in this article pertain to its investigation in preclinical models and clinical trials — not to its use outside of controlled research settings.
Why Triple Agonism Matters: Moving Beyond Single and Dual Targets
To appreciate the significance of retatrutide, it helps to understand the trajectory of incretin-based research.
First generation: Single GLP-1 receptor agonists. Compounds such as semaglutide and liraglutide target the GLP-1 receptor alone. Research has demonstrated that GLP-1 receptor activation enhances glucose-dependent insulin release, suppresses glucagon secretion (in a glucose-dependent manner), slows gastric emptying, and acts on central appetite-regulating pathways. These compounds have been extensively studied and have produced well-characterised metabolic effects in clinical research.
Second generation: Dual GLP-1/GIP receptor agonists. Tirzepatide, the most prominent example, activates both GLP-1 and GIP receptors. Clinical research — including the SURMOUNT and SURPASS trial programmes — demonstrated that this dual approach produced greater effects on glycaemic parameters and body weight reduction compared to GLP-1 receptor agonism alone. The addition of GIP receptor activity appears to amplify insulin secretion and may contribute to improved lipid handling and adipose tissue function.
Third generation: Triple GLP-1/GIP/glucagon receptor agonists. Retatrutide adds a third dimension by incorporating glucagon receptor agonism. This is a bold addition, because glucagon has traditionally been viewed primarily through its role in raising blood glucose — seemingly counterproductive in the context of metabolic research focused on glucose control. However, emerging research has revealed that glucagon receptor activation offers distinct metabolic benefits that are not accessible through GLP-1 or GIP pathways alone.
The rationale for triple agonism is not simply additive — it is synergistic. Each receptor pathway modulates different aspects of metabolic physiology, and their combined activation appears to produce effects that exceed what any single or dual approach can achieve in isolation.
Mechanism of Action: What Each Receptor Contributes
GLP-1 Receptor Agonism
GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient intake. In research models, GLP-1 receptor activation has been shown to:
Enhance glucose-dependent insulin secretion from pancreatic beta cells
Suppress inappropriate glucagon release from alpha cells
Delay gastric emptying, which slows nutrient absorption
Act on hypothalamic and brainstem circuits to reduce food intake in animal models
The GLP-1 component of retatrutide provides the well-established metabolic foundation that has been validated across numerous clinical trials with single-agonist compounds.
GIP Receptor Agonism
GIP is secreted by intestinal K-cells and has historically been less well understood than GLP-1. However, recent research has clarified its role considerably. GIP receptor activation in research models has been associated with:
Potentiation of glucose-dependent insulin secretion (complementary to but distinct from GLP-1 effects)
Modulation of lipid metabolism in adipose tissue
Potential protective effects on bone metabolism
Enhancement of the overall incretin response when combined with GLP-1 receptor activation
The inclusion of GIP agonism in retatrutide mirrors the approach validated by tirzepatide research, providing an amplified incretin signal.
Glucagon Receptor Agonism
This is where retatrutide diverges most significantly from its predecessors. Glucagon, produced by pancreatic alpha cells, has long been recognised for its role in stimulating hepatic glucose production. At first glance, activating the glucagon receptor might seem counterintuitive in metabolic research. However, the metabolic effects of glucagon extend well beyond glycaemia:
Increased energy expenditure: Glucagon receptor activation has been shown in preclinical research to increase resting energy expenditure, potentially through effects on brown adipose tissue thermogenesis and hepatic mitochondrial activity.
Enhanced lipid oxidation: Glucagon promotes hepatic fatty acid oxidation, which may contribute to reductions in liver fat content — a finding of particular interest for researchers studying hepatic steatosis.
Amino acid metabolism: Glucagon influences amino acid turnover and ureagenesis, adding another metabolic dimension.
Appetite modulation: Some preclinical evidence suggests glucagon may independently reduce food intake through central nervous system pathways, though this remains an active area of investigation.
Crucially, in the context of a triple-agonist compound, the potential hyperglycaemic effects of glucagon receptor activation appear to be counterbalanced by the concurrent GLP-1 and GIP receptor agonism, which enhance insulin secretion and improve glucose disposal. This pharmacological “balancing act” is one of the most compelling aspects of retatrutide’s design — the glucagon component contributes its unique metabolic benefits while the incretin components mitigate the glucose-raising risk.
Key Clinical Research: The Phase 2 Trial (Jastreboff et al., 2023)
The most significant clinical data for retatrutide to date comes from a Phase 2, dose-ranging trial published in The New England Journal of Medicine by Jastreboff and colleagues in 2023. This 48-week, randomised, double-blind, placebo-controlled study enrolled 338 adults with obesity and investigated multiple dose levels of retatrutide administered subcutaneously once weekly.
Study Design
Participants were randomised to receive placebo or one of several retatrutide dose regimens, ranging from 1 mg to 12 mg. The primary endpoint was percentage change in body weight from baseline at 24 weeks, with continued observation through 48 weeks.
Key Findings
The results were striking by the standards of metabolic peptide research:
At 48 weeks, participants in the highest dose group (12 mg) achieved a mean body weight reduction of approximately 24.2% from baseline.
Weight reduction was dose-dependent, with clear separation between dose groups emerging by 12 weeks.
More than 25% of participants in the 12 mg group achieved weight reductions exceeding 30% — a threshold rarely observed in prior clinical research with single- or dual-agonist compounds.
Improvements were also observed across multiple metabolic parameters, including glycaemic markers and lipid profiles.
The safety profile was broadly consistent with the GLP-1 receptor agonist class. Gastrointestinal adverse events (nausea, diarrhoea, vomiting) were the most commonly reported side effects, generally mild to moderate and most frequent during dose escalation.
Significance of These Findings
The magnitude of weight reduction observed in this trial exceeded what has been reported in comparable Phase 2 studies of tirzepatide and semaglutide at similar time points. While cross-trial comparisons must always be interpreted cautiously — differences in patient populations, study design, and dosing protocols can confound direct comparisons — the data nonetheless suggest that triple agonism may confer additional metabolic effects beyond what dual agonism provides.
The dose-response relationship was also particularly informative for researchers. The clear, graded effect across dose levels provides valuable pharmacological data about the relationship between receptor engagement and metabolic outcomes.
How Retatrutide Compares Mechanistically to Other Research Compounds
Understanding retatrutide’s place in the broader landscape of incretin-based research compounds requires a comparative perspective:
Feature
Semaglutide
Tirzepatide
Retatrutide
GLP-1 receptor agonism
Yes
Yes
Yes
GIP receptor agonism
No
Yes
Yes
Glucagon receptor agonism
No
No
Yes
Receptor classification
Mono-agonist
Dual agonist
Triple agonist
Energy expenditure effect
Minimal direct effect
Under investigation
Potentially significant (via glucagon)
Hepatic lipid metabolism
Indirect
Indirect
Direct (via glucagon)
The glucagon receptor component is what fundamentally distinguishes retatrutide. While GLP-1 and GIP receptor activation primarily influence insulin secretion, appetite, and nutrient handling, glucagon receptor activation introduces effects on the “expenditure side” of the energy balance equation. In research terms, this means retatrutide is the first clinical-stage compound to simultaneously target both energy intake and energy expenditure through direct receptor-mediated mechanisms.
This has particular implications for researchers investigating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The glucagon receptor’s role in promoting hepatic lipid oxidation makes retatrutide a compound of high interest for liver-focused metabolic research. Early clinical data have shown meaningful reductions in liver fat content in participants receiving retatrutide, an effect that may be at least partially attributable to the glucagon component.
Current State of Research and Future Directions
As of early 2026, retatrutide is being investigated in a comprehensive Phase 3 clinical trial programme. Key areas of active investigation include:
Obesity research: Large-scale, pivotal trials evaluating the compound’s effects on body weight and metabolic health markers over extended treatment periods.
Type 2 diabetes research: Trials investigating glycaemic outcomes in populations with established type 2 diabetes.
MASLD/MASH research (formerly NAFLD/NASH): Given the glucagon receptor’s hepatic effects, retatrutide is being studied for its potential impact on liver fat, inflammation, and fibrosis markers.
Cardiovascular outcomes: Longer-term studies are expected to assess the compound’s effects on cardiovascular risk markers, building on the cardiovascular outcomes data established by GLP-1 receptor agonist research.
Combination research: Investigating how triple agonism interacts with other metabolic interventions remains an area of scientific interest.
The broader research trajectory also points toward even more complex multi-agonist peptides in the future. Retatrutide’s demonstration that three receptor systems can be effectively engaged by a single molecule has opened the door for further exploration of polypharmacology in metabolic peptide design.
Handling and Storage Notes for Research Use
For researchers working with retatrutide in laboratory settings, proper handling and storage are essential for maintaining peptide integrity:
Storage: Lyophilised peptide should be stored at -20 degrees C or below, protected from light and moisture. Avoid repeated freeze-thaw cycles.
Reconstitution: Reconstitute with bacteriostatic water or sterile water according to the required concentration for your research protocol. Use aseptic technique throughout.
Post-reconstitution storage: Once reconstituted, store at 2-8 degrees C (refrigerated) and use within the timeframe specified by the supplier. Stability data vary by formulation.
Handling: Use appropriate laboratory PPE. Peptide solutions should be handled with calibrated pipettes for accurate dosing in experimental protocols.
Documentation: Maintain batch records, storage logs, and chain-of-custody documentation in accordance with your institution’s research protocols.
Conclusion
Retatrutide represents a genuine step-change in metabolic peptide research. By combining GLP-1, GIP, and glucagon receptor agonism in a single molecule, it offers researchers a tool that engages metabolic pathways no prior compound has been able to address simultaneously. The Phase 2 clinical data published by Jastreboff and colleagues demonstrated dose-dependent effects of a magnitude that has generated considerable scientific interest, and the ongoing Phase 3 programme will provide the larger-scale, longer-duration data needed to more fully characterise the compound’s research profile.
For the metabolic research community, retatrutide is not simply another incretin analogue — it is a proof of concept that multi-receptor polypharmacology can unlock metabolic effects that single-target approaches cannot reach. As clinical data continue to emerge, the compound is likely to remain a focal point for researchers investigating obesity, metabolic syndrome, hepatic steatosis, and the complex interplay between energy intake, energy expenditure, and substrate metabolism.
At Trusted Peptides, we are committed to supporting the research community with high-quality peptides and the information needed to use them effectively. All products are intended strictly for laboratory and research purposes.
Disclaimer: This article is for informational and educational purposes only. Retatrutide is a research compound and is not approved for human therapeutic use. All references to clinical trials describe controlled research investigations. Trusted Peptides products are sold for research use only and are not intended for human consumption.
References
Jastreboff, A.M., Kaplan, L.M., Frias, J.P., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. The New England Journal of Medicine, 389(6), 514-526.
Coskun, T., Urva, S., Roell, W.C., et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. The Journal of Clinical Investigation, 132(8), e154785.
Finan, B., Yang, B., Ottaway, N., et al. (2015). A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nature Medicine, 21(1), 27-36.
Retatrutide: The Triple-Agonist Peptide Redefining Metabolic Research
The landscape of metabolic peptide research has shifted dramatically over the past decade. From the early days of single-target GLP-1 receptor agonists to the more recent emergence of dual-agonist compounds like tirzepatide, each generation of incretin-based peptides has expanded what researchers thought possible in the study of metabolic regulation. Now, a new compound is pushing the boundary further still. Retatrutide (LY3437943), developed by Eli Lilly, is a triple-agonist peptide that simultaneously engages three distinct receptor systems: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This unprecedented triple mechanism has generated significant interest across the metabolic research community — and for good reason.
In this article, we explore what makes retatrutide unique at a molecular level, review the key clinical research findings published to date, and examine why this compound represents a meaningful step forward for researchers investigating metabolic pathways, energy homeostasis, and lipid metabolism.
What Is Retatrutide?
Retatrutide is a synthetic peptide that functions as an agonist at three G protein-coupled receptors central to metabolic regulation. Structurally, it is a single molecule engineered to bind and activate:
This makes retatrutide what is commonly referred to as a “triagonist” or “triple-agonist” — a single peptide capable of engaging all three receptor pathways simultaneously. The compound is based on a modified GIP peptide backbone, with amino acid substitutions and a fatty acid side chain that extends its half-life and enables once-weekly dosing in research protocols.
It is worth emphasising that retatrutide is classified as a research compound. All references in this article pertain to its investigation in preclinical models and clinical trials — not to its use outside of controlled research settings.
Why Triple Agonism Matters: Moving Beyond Single and Dual Targets
To appreciate the significance of retatrutide, it helps to understand the trajectory of incretin-based research.
First generation: Single GLP-1 receptor agonists. Compounds such as semaglutide and liraglutide target the GLP-1 receptor alone. Research has demonstrated that GLP-1 receptor activation enhances glucose-dependent insulin release, suppresses glucagon secretion (in a glucose-dependent manner), slows gastric emptying, and acts on central appetite-regulating pathways. These compounds have been extensively studied and have produced well-characterised metabolic effects in clinical research.
Second generation: Dual GLP-1/GIP receptor agonists. Tirzepatide, the most prominent example, activates both GLP-1 and GIP receptors. Clinical research — including the SURMOUNT and SURPASS trial programmes — demonstrated that this dual approach produced greater effects on glycaemic parameters and body weight reduction compared to GLP-1 receptor agonism alone. The addition of GIP receptor activity appears to amplify insulin secretion and may contribute to improved lipid handling and adipose tissue function.
Third generation: Triple GLP-1/GIP/glucagon receptor agonists. Retatrutide adds a third dimension by incorporating glucagon receptor agonism. This is a bold addition, because glucagon has traditionally been viewed primarily through its role in raising blood glucose — seemingly counterproductive in the context of metabolic research focused on glucose control. However, emerging research has revealed that glucagon receptor activation offers distinct metabolic benefits that are not accessible through GLP-1 or GIP pathways alone.
The rationale for triple agonism is not simply additive — it is synergistic. Each receptor pathway modulates different aspects of metabolic physiology, and their combined activation appears to produce effects that exceed what any single or dual approach can achieve in isolation.
Mechanism of Action: What Each Receptor Contributes
GLP-1 Receptor Agonism
GLP-1 is an incretin hormone secreted by intestinal L-cells in response to nutrient intake. In research models, GLP-1 receptor activation has been shown to:
The GLP-1 component of retatrutide provides the well-established metabolic foundation that has been validated across numerous clinical trials with single-agonist compounds.
GIP Receptor Agonism
GIP is secreted by intestinal K-cells and has historically been less well understood than GLP-1. However, recent research has clarified its role considerably. GIP receptor activation in research models has been associated with:
The inclusion of GIP agonism in retatrutide mirrors the approach validated by tirzepatide research, providing an amplified incretin signal.
Glucagon Receptor Agonism
This is where retatrutide diverges most significantly from its predecessors. Glucagon, produced by pancreatic alpha cells, has long been recognised for its role in stimulating hepatic glucose production. At first glance, activating the glucagon receptor might seem counterintuitive in metabolic research. However, the metabolic effects of glucagon extend well beyond glycaemia:
Crucially, in the context of a triple-agonist compound, the potential hyperglycaemic effects of glucagon receptor activation appear to be counterbalanced by the concurrent GLP-1 and GIP receptor agonism, which enhance insulin secretion and improve glucose disposal. This pharmacological “balancing act” is one of the most compelling aspects of retatrutide’s design — the glucagon component contributes its unique metabolic benefits while the incretin components mitigate the glucose-raising risk.
Key Clinical Research: The Phase 2 Trial (Jastreboff et al., 2023)
The most significant clinical data for retatrutide to date comes from a Phase 2, dose-ranging trial published in The New England Journal of Medicine by Jastreboff and colleagues in 2023. This 48-week, randomised, double-blind, placebo-controlled study enrolled 338 adults with obesity and investigated multiple dose levels of retatrutide administered subcutaneously once weekly.
Study Design
Participants were randomised to receive placebo or one of several retatrutide dose regimens, ranging from 1 mg to 12 mg. The primary endpoint was percentage change in body weight from baseline at 24 weeks, with continued observation through 48 weeks.
Key Findings
The results were striking by the standards of metabolic peptide research:
Significance of These Findings
The magnitude of weight reduction observed in this trial exceeded what has been reported in comparable Phase 2 studies of tirzepatide and semaglutide at similar time points. While cross-trial comparisons must always be interpreted cautiously — differences in patient populations, study design, and dosing protocols can confound direct comparisons — the data nonetheless suggest that triple agonism may confer additional metabolic effects beyond what dual agonism provides.
The dose-response relationship was also particularly informative for researchers. The clear, graded effect across dose levels provides valuable pharmacological data about the relationship between receptor engagement and metabolic outcomes.
How Retatrutide Compares Mechanistically to Other Research Compounds
Understanding retatrutide’s place in the broader landscape of incretin-based research compounds requires a comparative perspective:
The glucagon receptor component is what fundamentally distinguishes retatrutide. While GLP-1 and GIP receptor activation primarily influence insulin secretion, appetite, and nutrient handling, glucagon receptor activation introduces effects on the “expenditure side” of the energy balance equation. In research terms, this means retatrutide is the first clinical-stage compound to simultaneously target both energy intake and energy expenditure through direct receptor-mediated mechanisms.
This has particular implications for researchers investigating non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The glucagon receptor’s role in promoting hepatic lipid oxidation makes retatrutide a compound of high interest for liver-focused metabolic research. Early clinical data have shown meaningful reductions in liver fat content in participants receiving retatrutide, an effect that may be at least partially attributable to the glucagon component.
Current State of Research and Future Directions
As of early 2026, retatrutide is being investigated in a comprehensive Phase 3 clinical trial programme. Key areas of active investigation include:
The broader research trajectory also points toward even more complex multi-agonist peptides in the future. Retatrutide’s demonstration that three receptor systems can be effectively engaged by a single molecule has opened the door for further exploration of polypharmacology in metabolic peptide design.
Handling and Storage Notes for Research Use
For researchers working with retatrutide in laboratory settings, proper handling and storage are essential for maintaining peptide integrity:
Conclusion
Retatrutide represents a genuine step-change in metabolic peptide research. By combining GLP-1, GIP, and glucagon receptor agonism in a single molecule, it offers researchers a tool that engages metabolic pathways no prior compound has been able to address simultaneously. The Phase 2 clinical data published by Jastreboff and colleagues demonstrated dose-dependent effects of a magnitude that has generated considerable scientific interest, and the ongoing Phase 3 programme will provide the larger-scale, longer-duration data needed to more fully characterise the compound’s research profile.
For the metabolic research community, retatrutide is not simply another incretin analogue — it is a proof of concept that multi-receptor polypharmacology can unlock metabolic effects that single-target approaches cannot reach. As clinical data continue to emerge, the compound is likely to remain a focal point for researchers investigating obesity, metabolic syndrome, hepatic steatosis, and the complex interplay between energy intake, energy expenditure, and substrate metabolism.
At Trusted Peptides, we are committed to supporting the research community with high-quality peptides and the information needed to use them effectively. All products are intended strictly for laboratory and research purposes.
Disclaimer: This article is for informational and educational purposes only. Retatrutide is a research compound and is not approved for human therapeutic use. All references to clinical trials describe controlled research investigations. Trusted Peptides products are sold for research use only and are not intended for human consumption.
References